1. Home
  2. BLAC vs LUCD Comparison

BLAC vs LUCD Comparison

Compare BLAC & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLAC
  • LUCD
  • Stock Information
  • Founded
  • BLAC 2020
  • LUCD 2018
  • Country
  • BLAC United States
  • LUCD United States
  • Employees
  • BLAC N/A
  • LUCD N/A
  • Industry
  • BLAC
  • LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • BLAC
  • LUCD Health Care
  • Exchange
  • BLAC NYSE
  • LUCD Nasdaq
  • Market Cap
  • BLAC 26.3M
  • LUCD 51.6M
  • IPO Year
  • BLAC 2023
  • LUCD 2021
  • Fundamental
  • Price
  • BLAC $11.42
  • LUCD $0.93
  • Analyst Decision
  • BLAC
  • LUCD Strong Buy
  • Analyst Count
  • BLAC 0
  • LUCD 4
  • Target Price
  • BLAC N/A
  • LUCD $3.63
  • AVG Volume (30 Days)
  • BLAC 6.2K
  • LUCD 215.4K
  • Earning Date
  • BLAC 01-01-0001
  • LUCD 03-24-2025
  • Dividend Yield
  • BLAC N/A
  • LUCD N/A
  • EPS Growth
  • BLAC N/A
  • LUCD N/A
  • EPS
  • BLAC N/A
  • LUCD N/A
  • Revenue
  • BLAC N/A
  • LUCD $4,189,000.00
  • Revenue This Year
  • BLAC N/A
  • LUCD $91.72
  • Revenue Next Year
  • BLAC N/A
  • LUCD $139.38
  • P/E Ratio
  • BLAC N/A
  • LUCD N/A
  • Revenue Growth
  • BLAC N/A
  • LUCD 179.27
  • 52 Week Low
  • BLAC $10.56
  • LUCD $0.63
  • 52 Week High
  • BLAC $13.40
  • LUCD $1.46
  • Technical
  • Relative Strength Index (RSI)
  • BLAC 50.56
  • LUCD 59.37
  • Support Level
  • BLAC $11.27
  • LUCD $0.89
  • Resistance Level
  • BLAC $11.50
  • LUCD $0.96
  • Average True Range (ATR)
  • BLAC 0.31
  • LUCD 0.04
  • MACD
  • BLAC -0.02
  • LUCD 0.01
  • Stochastic Oscillator
  • BLAC 14.86
  • LUCD 76.95

About BLAC BELLEVUE LIFE SCIENCES ACQ CORP

Bellevue Life Sciences Acquisition Corp is a blank check company.

About LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Share on Social Networks: